Abstract
This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström's macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.
Bidragets oversatte titel | Monoclonal gammopathy of undetermined significance |
---|---|
Originalsprog | Dansk |
Artikelnummer | V08190428 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 182 |
Udgave nummer | 10 |
Antal sider | 5 |
ISSN | 0041-5782 |
Status | Udgivet - 2 mar. 2020 |
Udgivet eksternt | Ja |
Emneord
- Humans
- Immunoglobulin Light-chain Amyloidosis
- Monoclonal Gammopathy of Undetermined Significance/diagnosis
- Multiple Myeloma
- Waldenstrom Macroglobulinemia/diagnosis